Show simple item record

FieldValueLanguage
dc.contributor.authorArentz, Susanen
dc.contributor.authorYang, Guoyanen
dc.contributor.authorGoldenberg, Joshuaen
dc.contributor.authorBeardsley, Jenniferen
dc.contributor.authorMyers, Stephen P.en
dc.contributor.authorMertz, Dominiken
dc.contributor.authorLeeder, Stephenen
dc.contributor.authorHunter, Jenniferen
dc.date.accessioned2020-08-14
dc.date.available2020-08-14
dc.date.issued2020en
dc.identifier.urihttps://hdl.handle.net/2123/23052
dc.description.abstractAs of 9 June 2020, indirect evidence from other types of viral respiratory infections suggests that zinc may potentially reduce the risk, duration and severity of SARS-CoV-2 infections; particularly for populations at risk of zinc deficiency. Notably, people with chronic disease co-morbidities and older adults are at risk of lower zinc status. Pending the results of SARS-CoV-2 clinical trials, clinicians might consider assessing zinc status as part of a SARS-CoV-2 clinical work-up to determine if short-term zinc supplementation, either orally or intravenously is indicated for those with low or borderline low results, low dietary intake and/or increased needs.en
dc.language.isoenen
dc.rightsOther
dc.subjectCOVID-19en
dc.subjectCoronavirusen
dc.titleClinical significance summary: Preliminary results of a rapid review of zinc for the prevention and treatment of SARS-CoV-2 and other acute viral respiratory infectionsen
dc.typeArticleen
dc.identifier.doi10.1016/j.aimed.2020.07.009
usyd.facultyFaculty of Medicine and Health, Sydney Medical Schoolen


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.